Clinical trials of off-the-shelf allogeneic CAR-NK (natural killer) cell therapies demonstrate durable remissions in relapsed/refractory Hodgkin’s lymphoma patients without causing graft-versus-host disease or cytokine release syndrome, establishing a scalable alternative to autologous CAR-T manufacturing. science.org